scholarly journals Using Mesenchymal Stem Cells to Treat Female Infertility: An Update on Female Reproductive Diseases

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Yun-xia Zhao ◽  
Shao-rong Chen ◽  
Ping-ping Su ◽  
Feng-huang Huang ◽  
Yan-chuan Shi ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Ethical Issues ◽  
Polycystic Ovary ◽  
Well Being ◽  
Female Infertility ◽  
Tube Obstruction ◽  
Fallopian Tube Obstruction ◽  
Uterine Diseases

Female infertility impacts the quality of life and well-being of affected individuals and couples. Female reproductive diseases, such as primary ovarian insufficiency, polycystic ovary syndrome, endometriosis, fallopian tube obstruction, and Asherman syndrome, can induce infertility. In recent years, translational medicine has developed rapidly, and clinical researchers are focusing on the treatment of female infertility using novel approaches. Owing to the advantages of convenient samples, abundant sources, and avoidable ethical issues, mesenchymal stem cells (MSCs) can be applied widely in the clinic. This paper reviews recent advances in using four types of MSCs, bone marrow stromal cells, adipose-derived stem cells, menstrual blood mesenchymal stem cells, and umbilical cord mesenchymal stem cells. Each of these have been used for the treatment of ovarian and uterine diseases, and provide new approaches for the treatment of female infertility.

scholarly journals Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

2020 ◽  
Author(s):  
Sahar Esfandyari ◽  
Rishi Man Chugh ◽  
Hang-Soo Park ◽  
Elie Hobeika ◽  
Mara Ulin ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Medical Condition ◽  
Polycystic Ovary ◽  
High Capacity ◽  
Female Infertility ◽  
Great Promise ◽  
Cell Based Therapy ◽  
Therapeutic Outcomes ◽  
Cell Sources

Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency and to improve reproductive health for a significant number of women worldwide.

scholarly journals Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

Cells ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 2253
Author(s):  
Sahar Esfandyari ◽  
Rishi Man Chugh ◽  
Hang-soo Park ◽  
Elie Hobeika ◽  
Mara Ulin ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Medical Condition ◽  
Polycystic Ovary ◽  
High Capacity ◽  
Female Infertility ◽  
Great Promise ◽  
Cell Based Therapy ◽  
Therapeutic Outcomes ◽  
Cell Sources

Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy, with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency, and to improve reproductive health for a significant number of women worldwide.

Mesenchymal Stem Cells in the Treatment of Cartilage Defects of the Knee: A Systematic Review of the Clinical Outcomes

2021 ◽  
pp. 036354652098681
Author(s):  
Monketh Jaibaji ◽  
Rawan Jaibaji ◽  
Andrea Volpin
Keyword(s):  
Systematic Review ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Osteochondral Lesions ◽  
Common Source ◽  
Significant Heterogeneity ◽  
Osteochondral Defects

Background: Osteochondral lesions are a common clinical problem and their management has been historically challenging. Mesenchymal stem cells have the potential to differentiate into chondrocytes and thus restore hyaline cartilage to the defect, theoretically improving clincal outcomes in these patients. They can also be harvested with minimal donor site morbidity. Purpose: To assess the clinical and functional outcomes of mesenchymal stem cell implantation to treat isolated osteochondral defects of the knee. A secondary purpose is to assess the quality of the current available evidence as well as the radiological and histological outcomes. We also reviewed the cellular preparation and operative techniques for implantation. Study Design: Systematic review. Methods: A comprehensive literature search of 4 databases was carried out: CINAHL, Embase, MEDLINE, and PubMed. We searched for clinical studies reporting the outcomes on a minimum of 5 patients with at least 12 months of follow-up. Clinical, radiological, and histological outcomes were recorded. We also recorded demographics, stem cell source, culture technique, and operative technique. Methodological quality of each study was assessed using the modified Coleman methodology score, and risk of bias for the randomized controlled studies was assessed using the Cochrane Collaboration tool. Results: Seventeen studies were found, encompassing 367 patients. The mean patient age was 35.1 years. Bone marrow was the most common source of stem cells utilized. Mesenchymal stem cell therapy consistently demonstrated good short- to medium-term outcomes in the studies reviewed with no serious adverse events being recorded. There was significant heterogeneity in cell harvesting and preparation as well as in the reporting of outcomes. Conclusion: Mesenchymal stem cells demonstrated a clinically relevant improvement in outcomes in patients with osteochondral defects of the knee. More research is needed to establish an optimal treatment protocol, long-term outcomes, and superiority over other therapies. Registration: CRD42020179391 (PROSPERO).

scholarly journals Adipose Derived-Mesenchymal Stem Cells Viability and Differentiating Features for Orthopaedic Reparative Applications: Banking of Adipose Tissue

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Ilaria Roato ◽  
Daniela Alotto ◽  
Dimas Carolina Belisario ◽  
Stefania Casarin ◽  
Mara Fumagalli ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Adipose Tissue ◽  
Articular Cartilage ◽  
Tissue Banking ◽  
Stromal Vascular Fraction ◽  
Single Infusion ◽  
Knee Arthritis ◽  
Symptomatic Knee

Osteoarthritis is characterized by loss of articular cartilage also due to reduced chondrogenic activity of mesenchymal stem cells (MSCs) from patients. Adipose tissue is an attractive source of MSCs (ATD-MSCs), representing an effective tool for reparative medicine, particularly for treatment of osteoarthritis, due to their chondrogenic and osteogenic differentiation capability. The treatment of symptomatic knee arthritis with ATD-MSCs proved effective with a single infusion, but multiple infusions could be also more efficacious. Here we studied some crucial aspects of adipose tissue banking procedures, evaluating ATD-MSCs viability, and differentiation capability after cryopreservation, to guarantee the quality of the tissue for multiple infusions. We reported that the presence of local anesthetic during lipoaspiration negatively affects cell viability of cryopreserved adipose tissue and cell growth of ATD-MSCs in culture. We observed that DMSO guarantees a faster growth of ATD-MSCs in culture than trehalose. At last, ATD-MSCs derived from fresh and cryopreserved samples at −80°C and −196°C showed viability and differentiation ability comparable to fresh samples. These data indicate that cryopreservation of adipose tissue at −80°C and −196°C is equivalent and preserves the content of ATD-MSCs in Stromal Vascular Fraction (SVF), guaranteeing the differentiation ability of ATD-MSCs.

scholarly journals Neonatal derived mesenchymal stem cell mesotherapy in androgenetic alopecia: a retrospective observational study and review of literature

2015 ◽  
Vol 1 (1) ◽  
pp. 32 ◽  
Author(s):  
Leelavathy Budamakuntla ◽  
Eswari Loganathan ◽  
Shwetha Suryanarayana ◽  
Aparna Dongre
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Observational Study ◽  
Ethical Issues ◽  
Dermal Papilla ◽  
External Source ◽  
Androgenetic Alopecia ◽  
Randomized Controlled Studies ◽  
Stem Cell Treatment

<p class="abstract"><strong>Background:</strong> Androgenetic alopecia has been a stressful condition for the patients and treating dermatologists alike. With the advent of stem cell therapy in various diseases, and lot of controversies and ethical issues related to it, mesenchymal stem cells MSC have passed the acid test successfully, though with many challenges. Since the stem cells in the hair follicle bulge and the dermal papilla play an important role in hair cycle and growth, introducing an external source of neonatal mesenchymal stem cells seems to be a possibility in the treatment of AGA. Aims: To know the benefits and safety of stem cell treatment in patients who underwent mesotherapy with neonatal MSC in order to establish the safety and efficacy in the treatment of AGA.</p><p class="abstract"><strong>Methods:</strong> We collected data of 40 patients treated with mesoinjections of commercially prepared neonatal MSC, with AGA of grade 2 to 7. Before and after photographs, Patient (PtGA) and Physician (PGA) Global assessment scores were used to evaluate the treatment response.</p><p class="abstract"><strong>Results:</strong> We found that 70% of the patients showed a mild response and 25% of them showed a moderate improvement in the hair growth and reduction in hair loss after 4 sittings of monthly duration. One subject showed an improvement of 72%. Patients had 6 month follow up. No major adverse events were observed.</p><p class="abstract"><strong>Conclusions:</strong> Since this is an observational study, large randomized controlled studies, with longer follow ups is recommended to make MSC therapy a novel treatment option for AGA. </p><strong>Keywords: </strong>Mesenchymal stem cells, Mesotherapy, Androgenetic alopecia

scholarly journals Current Status of Canine Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Veterinary Medicine

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Tania Sultana ◽  
Soojung Lee ◽  
Hun-Young Yoon ◽  
Jeong Ik Lee
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Adipose Tissue ◽  
Veterinary Medicine ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Ethical Issues ◽  
Treatment Strategies ◽  
Current Status

Stem cell therapy has prompted the expansion of veterinary medicine both experimentally and clinically, with the potential to contribute to contemporary treatment strategies for various diseases and conditions for which limited or no therapeutic options are presently available. Although the application of various types of stem cells, such as bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived mesenchymal stem cells (AT-MSCs), and umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), has promising potential to improve the health of different species, it is crucial that the benefits and drawbacks are completely evaluated before use. Umbilical cord blood (UCB) is a rich source of stem cells; nonetheless, isolation of mesenchymal stem cells (MSCs) from UCB presents technical challenges. Although MSCs have been isolated from UCB of diverse species such as human, equine, sheep, goat, and canine, there are inherent limitations of using UCB from these species for the expansion of MSCs. In this review, we investigated canine UCB (cUCB) and compared it with UCB from other species by reviewing recent articles published from February 2003 to June 2017 to gain an understanding of the limitations of cUCB in the acquisition of MSCs and to determine other suitable sources for the isolation of MSCs from canine. Our review indicates that cUCB is not an ideal source of MSCs because of insufficient volume and ethical issues. However, canine reproductive organs discarded during neutering may help broaden our understanding of effective isolation of MSCs. We recommend exploring canine reproductive and adipose tissue rather than UCB to fulfill the current need in veterinary medicine for the well-designed and ethically approved source of MSCs.

Sign in / Sign up

Export Citation Format

Share Document